drug
meningococcal [serotypes A, C, W-135, Y] vaccine
Marketedupdated 6mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
Trials studying meningococcal [serotypes A, C, W-135, Y] vaccine
- phase2Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
- phase3Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
- phase1Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old
- phase3Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
News(1)
- GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steamUp to 1,217 GSK employees in Belgium are at risk of losing their jobs as the Big Pharma rolls out its global cost-saving plans.fiercebiotech · 1mo ago
Data sources
last refreshed 8h ago
Found something off?
comments(0)
5-min edit window · permanent after that